Related Experiment Video
Updated: May 11, 2026
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
[Active surveillance for low-risk prostate cancer]
1Service d'urologie, hôpital Saint-Louis, AP-HP, université Paris-7, Paris, France. g.ploussard@gmail.com
La Revue Du Praticien
|May 21, 2013
Summary
Active surveillance for low-risk prostate cancer is a safe strategy, reducing overtreatment risks. Careful patient selection and long-term monitoring are crucial for optimal oncologic outcomes.
Area of Science:
- Oncology
- Urology
Context:
- Increasing incidence of low-risk prostate cancer necessitates refined management strategies.
- Active surveillance is gaining acceptance to mitigate overtreatment risks and functional side effects.
Purpose:
- To evaluate the oncologic safety and efficacy of active surveillance for low-risk prostate cancer.
- To highlight the importance of precise patient selection and long-term follow-up in active surveillance protocols.
Summary:
- Active surveillance involves strict monitoring for disease progression, allowing timely intervention with radical treatment if needed, while avoiding unnecessary procedures for stable disease.
- Short- and mid-term follow-up data confirm the oncologic safety of active surveillance, with approximately 30% of patients eventually requiring deferred treatment.
- Current guidelines recommend active surveillance, but consensus on inclusion criteria is lacking, emphasizing the need for improved diagnostic tools like MRI and biomarkers.
Impact:
- Active surveillance enables patients to avoid potential functional consequences associated with radical treatments.
- Improved selection of candidates for active surveillance, particularly addressing the risk of undergrading at diagnosis, is critical.
- Long-term confirmation of oncologic outcomes is necessary due to the slow progression rate of low-risk prostate cancers.
